Logo of Neurotech International (ASX:NTI)Latest Neurotech International (ASX:NTI) News

Page 4
Page 4 of 4

Neurotech’s NTI164 Shows Rapid Absorption and Safety in Human PK Study

Neurotech International has reported positive human pharmacokinetic results for NTI164, a cannabinoid formulation designed for paediatric neurological disorders, confirming rapid absorption and a non-intoxicating profile.
Ada Torres
2 June 2025

Neurotech’s NTI164 Clears Key Safety Hurdle in 28-Day Toxicology Trials

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.
Ada Torres
5 May 2025

Neurotech Accelerates Pediatric Cannabinoid Therapy with European Partner

Neurotech International has inked a development deal with RH Farma to produce a pharmaceutical-grade cannabinoid drug targeting pediatric neurodevelopmental disorders, leveraging advanced European extraction technology.
Ada Torres
13 Feb 2025

Neurotech Boosts Cash Reserves with $2.44M R&D Tax Refund

Neurotech International has secured a $2.44 million R&D tax incentive refund, strengthening its cash position as it advances clinical trials for paediatric neurological disorders and prepares for regulatory submissions in FY2025.
Ada Torres
31 Jan 2025

Neurotech Advances Rett Syndrome Therapy with FDA Orphan Drug Nod

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.
Ada Torres
29 Jan 2025